NGM · Biotechnology

Liminatus Pharma, Inc. Class A Common Stock (LIMN) Stock

$0.10 -8.39% NGM: LIMN Healthcare

Liminatus Pharma, Inc. is an immuno-oncology firm, currently in its clinical development phase, dedicated to pioneering new treatments for cancer.

Valuation

MetricValue
Price$0.10
Market Cap$2.73M
P/E Ratio-0.27
P/B Ratio-19.87
P/S Ratio0.00
EPS (TTM)$-0.43
52-Week High$8.89
52-Week Low$0.10
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE215.73%
ROA-394.33%
ROCE33.33%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity-10.88
Current Ratio0.10

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-3.0M$-3.0M$-3.0M$-3.0M$-3.0M
Net Profit$4.0M$-3.0M$-1.0M$-3.0M$-10.0M
EPS$0.13$-0.08$-0.15$-0.40$-0.43
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$276.0M$15.0M$5.0M$3.0M$1.0M
Total Liabilities$22.0M$14.0M$15.0M$19.0M$10.0M
Cash$0$5.0M$0$1.0M$0
Borrowings$0$17.0M$16.0M$5.0M$1.0M

Latest News

BC-Most Active Stocks Associated Press · Jul 16, 2026 Top Premarket Gainers MT Newswires · Jul 2, 2026 Sector Update: Healthcare Stocks Edge Higher Premarket Wednesday MT Newswires · Jul 1, 2026 Liminatus Pharma Amends Merger Deal With InnocsAI MT Newswires · Jul 1, 2026 Liminatus Pharma Amends Definitive Merger Agreement with InnocsAI to Expand Oncology Cell Therapy Pipeline GlobeNewswire · Jun 30, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-1.0M$-1.0M$-3.0M$-3.0M$-10.0M
Investing Cash Flow$-276.0M$0$-1.0M$2.0M$-1.0M
Financing Cash Flow$-6.0M$-1.0M$0$-2.0M$-3.0M
Net Cash Flow$0$5.0M$-5.0M$1.0M$0
Free Cash Flow$-1.0M$-1.0M$-3.0M$-3.0M$-10.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA-0.21
FCF Yield-366.80%
Quick Ratio0.10
Interest Coverage-31.96
Return 1Y-97.95%
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ATHEAlterity Therapeutics Limited $4.70 -5.62% -6.89 $42.60M 0.00%
BTAIBioXcel Therapeutics, Inc. $0.87 +2.30% -0.13 $26.77M 0.00%
DYAIDyadic International, Inc. $1.17 -1.68% -5.59 $42.63M 0.00%
EVAXEvaxion Biotech A/S $3.05 +0.66% -1.99 $19.27M 0.00%
GBIOGeneration Bio Co. $5.34 +0.00% -0.87 $35.98M 0.00%

About Liminatus Pharma, Inc. Class A Common Stock

Liminatus Pharma, Inc. is an immuno-oncology firm, currently in its clinical development phase, dedicated to pioneering new treatments for cancer. The company's headquarters are located in La Palma, California.

Liminatus Pharma, Inc. Class A Common Stock is led by CEO Chris Kim, employs 3 people, headquartered in US, publicly traded since 2025.

Liminatus Pharma, Inc. Class A Common Stock (LIMN) stock trades at $0.10 with a market capitalization of $2.73M. The stock is valued at a price-to-earnings (P/E) ratio of -0.27, price-to-book of -19.87, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.10 and $8.89, and currently trades 98.9% below its 52-week high.

On profitability, Liminatus Pharma, Inc. Class A Common Stock generates a return on equity (ROE) of 215.73% — well above the market average, a sign of a high-quality business, return on capital employed of 33.33%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: liminatuspharma.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides